BridgeBio Pharma, Inc. Gains 51.98%
Mon, Mar 06, 2023 at 07:09 PM
BridgeBio Pharma, Inc. (BBIO:NASDAQ) jumped higher at $16.52, representing a gain of 52%. On Mon, Mar 06, 2023, BBIO:NASDAQ touched a New 2-Week High of $16.52. The stock got featured on our News Catalysts scanner on Mon, Mar 06, 2023 at 05:33 PM in the 'MISCELLANEOUS' category. From Tue, Feb 21, 2023, the stock recorded 22.22% Up Days and 30.00% Green Days
About BridgeBio Pharma, Inc. (BBIO:NASDAQ)
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Oncology and Gene therapy.
Top 10 Gainers:
- Appreciate Holdings Inc Cl A (SFR:NASDAQ), 159.32%
- Unicycive Therapeutics Inc. (UNCY:NASDAQ), 153.06%
- Ambrx Biopharma Inc. American Depositary Shares (each representing seven) (AMAM:NYSE), 95.02%
- Bellerophon Therapeutics, Inc. (BLPH:NASDAQ), 92.86%
- Genelux Corporation (GNLX:NASDAQ), 60.42%
- Orchestra BioMed Holdings Inc Com (OBIO:NASDAQ), 58.09%
- Vallon Pharmaceuticals Inc. (VLON:NASDAQ), 54.64%
- Avalon GloboCare Corp. (ALBT:NASDAQ), 53.92%
- BridgeBio Pharma, Inc. (BBIO:NASDAQ), 51.98%
- Troika Media Group Inc. (TRKA:NASDAQ), 48.64%